Smtp-7 derivative and use thereof
AssigneesShanghai Senhui Medicine Co., Ltd., Shanghai Shengdi Pharmaceutical Co., Ltd., Jiangsu Hengrui Pharmaceuticals Co., Ltd.
InventorsLingjian Zhu, Xiuzhao Yu, Xiaowu Liu, Peipei Ben, Lei Chen, Xianglin Kong, Jian Huang, Piaoyang Sun
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to an SMTP-7 derivative and the use thereof. In particular, provided is a compound as represented by formula I or a pharmaceutically acceptable salt thereof, wherein each group is as defined in the description.
Claims27
A compound of formula I or a pharmaceutically acceptable salt thereof,
- wherein F1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13 , R14 , R15, R16, R17, R18, R19,R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, R35, R36, R37, R38, R39, R40, R41, R42, R43, R44, R45, R46, R47, R48, R49, R50, R51, R52, R53, R54, R55, R56, R57, R58, R59, R60, R61, R62 and R63 are each independently hydrogen or deuterium, and at least one of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10-, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, R35, R36, R37, R38, R39, R40, R41, R42, R43, R44, R45, R46, R47, R48, R49, R50, R51, R52, R53, R54, R55, R56, R57, R58, R59, R60, R61, R62and R63 is deuterium.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.